annual cash & cash equivalents:
$4.57B-$5.80B(-55.93%)Summary
- As of today (August 23, 2025), VRTX annual cash & cash equivalents is $4.57 billion, with the most recent change of -$5.80 billion (-55.93%) on December 31, 2024.
- During the last 3 years, VRTX annual cash & cash equivalents has fallen by -$2.23 billion (-32.75%).
- VRTX annual cash & cash equivalents is now -56.50% below its all-time high of $10.50 billion, reached on December 31, 2022.
Performance
VRTX Cash and cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly cash & cash equivalents:
$6.39B+$180.70M(+2.91%)Summary
- As of today (August 23, 2025), VRTX quarterly cash & cash equivalents is $6.39 billion, with the most recent change of +$180.70 million (+2.91%) on June 30, 2025.
- Over the past year, VRTX quarterly cash & cash equivalents has increased by +$597.10 million (+10.30%).
- VRTX quarterly cash & cash equivalents is now -46.44% below its all-time high of $11.93 billion, reached on September 30, 2023.
Performance
VRTX quarterly cash & cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash and cash equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
VRTX Cash and cash equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -55.9% | +10.3% |
| 3 y3 years | -32.8% | -30.9% |
| 5 y5 years | +47.0% | +17.2% |
VRTX Cash and cash equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -56.5% | at low | -46.4% | +10.3% |
| 5 y | 5-year | -56.5% | +47.0% | -46.4% | +17.2% |
| alltime | all time | -56.5% | >+9999.0% | -46.4% | >+9999.0% |
VRTX Cash and cash equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2025 | - | $6.39B(+2.9%) |
| Mar 2025 | - | $6.21B(+1.5%) |
| Dec 2024 | $4.57B(-55.9%) | $6.12B(-6.4%) |
| Sep 2024 | - | $6.53B(+12.7%) |
| Jun 2024 | - | $5.80B(-43.0%) |
| Mar 2024 | - | $10.17B(-9.4%) |
| Dec 2023 | $10.37B(-1.3%) | $11.22B(-6.0%) |
| Sep 2023 | - | $11.93B(+6.2%) |
| Jun 2023 | - | $11.24B(+7.9%) |
| Mar 2023 | - | $10.42B(-3.4%) |
| Dec 2022 | $10.50B(+54.6%) | $10.79B(+10.3%) |
| Sep 2022 | - | $9.78B(+5.6%) |
| Jun 2022 | - | $9.26B(+12.3%) |
| Mar 2022 | - | $8.24B(+9.5%) |
| Dec 2021 | $6.79B(+13.5%) | $7.53B(+8.1%) |
| Sep 2021 | - | $6.97B(+3.7%) |
| Jun 2021 | - | $6.72B(-3.1%) |
| Mar 2021 | - | $6.93B(+4.1%) |
| Dec 2020 | $5.99B(+92.6%) | $6.66B(+8.2%) |
| Sep 2020 | - | $6.15B(+12.8%) |
| Jun 2020 | - | $5.46B(+29.9%) |
| Mar 2020 | - | $4.20B(+281.1%) |
| Dec 2019 | $3.11B(+17.3%) | - |
| Dec 2018 | $2.65B(+59.1%) | - |
| Dec 2017 | $1.67B(+40.7%) | - |
| Dec 2016 | $1.18B(+65.6%) | - |
| Mar 2016 | - | $1.10B(-0.3%) |
| Dec 2015 | $714.77M(+14.3%) | - |
| Jun 2015 | - | $1.10B(+8.2%) |
| Dec 2014 | $625.26M(+9.8%) | - |
| Dec 2013 | $569.30M(+16.3%) | - |
| Dec 2012 | $489.41M(+3.0%) | - |
| Dec 2011 | $475.32M(+95.4%) | $1.02B(+43.9%) |
| Sep 2011 | - | $709.26M(-27.6%) |
| Dec 2010 | $243.20M(-45.6%) | - |
| Jun 2010 | - | $979.14M(+65.1%) |
| Dec 2009 | $446.66M(+14.8%) | - |
| Dec 2008 | $389.12M(+9.4%) | - |
| Dec 2007 | $355.66M(+66.8%) | - |
| Jun 2007 | - | $592.97M(+67.3%) |
| Mar 2007 | - | $354.33M(+66.2%) |
| Dec 2006 | $213.17M(+173.1%) | $213.17M(-55.9%) |
| Sep 2006 | - | $483.43M(+1066.9%) |
| Jun 2006 | - | $41.43M(-49.4%) |
| Mar 2006 | - | $81.83M(+4.8%) |
| Dec 2005 | $78.05M(+41.9%) | $78.05M(-23.2%) |
| Sep 2005 | - | $101.62M(-47.8%) |
| Jun 2005 | - | $194.69M(+421.0%) |
| Mar 2005 | - | $37.37M(-32.1%) |
| Dec 2004 | $55.01M | $55.01M(+48.5%) |
| Sep 2004 | - | $37.04M(-41.8%) |
| Jun 2004 | - | $63.69M(+20.2%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2004 | - | $53.01M(-46.0%) |
| Dec 2003 | $98.16M(-9.2%) | $98.16M(+26.7%) |
| Sep 2003 | - | $77.45M(-41.9%) |
| Jun 2003 | - | $133.41M(-26.2%) |
| Mar 2003 | - | $180.77M(+67.2%) |
| Dec 2002 | $108.10M(-42.9%) | $108.10M(+4.3%) |
| Sep 2002 | - | $103.59M(-17.3%) |
| Jun 2002 | - | $125.27M(-28.9%) |
| Mar 2002 | - | $176.23M(-6.9%) |
| Dec 2001 | $189.21M(-45.4%) | $189.21M(-3.4%) |
| Sep 2001 | - | $195.95M(+16.3%) |
| Jun 2001 | - | $168.53M(-24.3%) |
| Mar 2001 | - | $222.66M(-35.8%) |
| Dec 2000 | $346.66M(+998.8%) | $346.66M(-26.5%) |
| Sep 2000 | - | $471.43M(+157.3%) |
| Jun 2000 | - | $183.21M(-4.5%) |
| Mar 2000 | - | $191.75M(+507.8%) |
| Dec 1999 | $31.55M(+30.4%) | $31.55M(+40.8%) |
| Sep 1999 | - | $22.40M(+100.0%) |
| Jun 1999 | - | $11.20M(-43.4%) |
| Mar 1999 | - | $19.80M(-18.2%) |
| Dec 1998 | $24.20M(-66.2%) | $24.20M(-51.3%) |
| Sep 1998 | - | $49.70M(+36.9%) |
| Jun 1998 | - | $36.30M(-37.8%) |
| Mar 1998 | - | $58.40M(-18.3%) |
| Dec 1997 | $71.50M(+104.9%) | $71.50M(-59.7%) |
| Sep 1997 | - | $177.20M(-6.0%) |
| Jun 1997 | - | $188.60M(+122.1%) |
| Mar 1997 | - | $84.90M(+143.3%) |
| Dec 1996 | $34.90M(+22.9%) | $34.90M(-10.7%) |
| Sep 1996 | - | $39.10M(+320.4%) |
| Jun 1996 | - | $9.30M(-54.0%) |
| Mar 1996 | - | $20.20M(-28.9%) |
| Dec 1995 | $28.40M(-60.3%) | $28.40M(-27.9%) |
| Sep 1995 | - | $39.40M(-10.7%) |
| Jun 1995 | - | $44.10M(-14.2%) |
| Mar 1995 | - | $51.40M(-28.2%) |
| Dec 1994 | $71.60M(+150.3%) | $71.60M(+47.6%) |
| Sep 1994 | - | $48.50M(+127.7%) |
| Jun 1994 | - | $21.30M(-60.8%) |
| Mar 1994 | - | $54.30M(+89.9%) |
| Dec 1993 | $28.60M(+146.6%) | $28.60M(+90.7%) |
| Sep 1993 | - | $15.00M(+130.8%) |
| Jun 1993 | - | $6.50M(-56.7%) |
| Mar 1993 | - | $15.00M(+29.3%) |
| Dec 1992 | $11.60M(-58.0%) | $11.60M(-48.9%) |
| Sep 1992 | - | $22.70M(+39.3%) |
| Jun 1992 | - | $16.30M(-34.3%) |
| Mar 1992 | - | $24.80M(-10.1%) |
| Dec 1991 | $27.60M(+527.3%) | $27.60M(+273.0%) |
| Sep 1991 | - | $7.40M(+221.7%) |
| Jun 1991 | - | $2.30M(-47.7%) |
| Dec 1990 | $4.40M | $4.40M |
FAQ
- What is Vertex Pharmaceuticals Incorporated annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Vertex Pharmaceuticals Incorporated?
- What is Vertex Pharmaceuticals Incorporated annual cash & cash equivalents year-on-year change?
- What is Vertex Pharmaceuticals Incorporated quarterly cash & cash equivalents?
- What is the all time high quarterly cash & cash equivalents for Vertex Pharmaceuticals Incorporated?
- What is Vertex Pharmaceuticals Incorporated quarterly cash & cash equivalents year-on-year change?
What is Vertex Pharmaceuticals Incorporated annual cash & cash equivalents?
The current annual cash & cash equivalents of VRTX is $4.57B
What is the all time high annual cash & cash equivalents for Vertex Pharmaceuticals Incorporated?
Vertex Pharmaceuticals Incorporated all-time high annual cash & cash equivalents is $10.50B
What is Vertex Pharmaceuticals Incorporated annual cash & cash equivalents year-on-year change?
Over the past year, VRTX annual cash & cash equivalents has changed by -$5.80B (-55.93%)
What is Vertex Pharmaceuticals Incorporated quarterly cash & cash equivalents?
The current quarterly cash & cash equivalents of VRTX is $6.39B
What is the all time high quarterly cash & cash equivalents for Vertex Pharmaceuticals Incorporated?
Vertex Pharmaceuticals Incorporated all-time high quarterly cash & cash equivalents is $11.93B
What is Vertex Pharmaceuticals Incorporated quarterly cash & cash equivalents year-on-year change?
Over the past year, VRTX quarterly cash & cash equivalents has changed by +$597.10M (+10.30%)